ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T Cell"

  • Abstract Number: 0010 • ACR Convergence 2024

    Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells

    Holly Wobma1, Francesca Alvarez-Calderon2, Jiayi Dong2, Alexandre Albanese2, Kayleigh Omdahl2, Rene Bermea3, Gillian Selig4, Marlana Winschel2, Elisa Rojas Palato2, Katherine Michaelis1, Xianliang Rui2, Bruce Blazar5, Susan Prockop2, Victor Tkachev3, Ulrike Gerdemann2 and Leslie Kean2, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, 3Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 4Harvard College, Boston, MA, 5Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN

    Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
  • Abstract Number: 0781 • ACR Convergence 2024

    An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD

    Takanori Sasaki1, Ye Cao2, Kathryne Marks3, Richard Ainsworth4, Kim Taylor5, Nunzio Bottini4, Mehreen Elahee6, Mari Kamiya3, Edy Kim6, Francesco Boin4 and Deepak Rao7, 1Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5University of California, San Francisco, CA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify circulating immune cells associated…
  • Abstract Number: 1415 • ACR Convergence 2024

    Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, Alan Baer2, Thomas Grader-Beck3, Margaret Beach4, Blake M. Warner5, Christopher Lessard1, A. Darise Farris1 and Robert Hal Scofield1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins, Baltimore, MD, 4NIH/NIDCR, Arlington, VA, 5National Institutes of Health, Bethesda, MD

    Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE…
  • Abstract Number: 1804 • ACR Convergence 2024

    Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
  • Abstract Number: 1854 • ACR Convergence 2024

    TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases

    Christopher VanDeusen1, Shannon Dwyer2, Aldo Borroto3, Andres Gagete1, D Scott Batty Jr1 and Balbino Alarcon3, 1Artax Biopharma, Inc, Cambridge, MA, 2Artax Biopharma, Inc., Cambridge, 3Centro de Biología Molecular Severo Ochoa, Madrid, Spain

    Background/Purpose: Loss of T-cell tolerance to self-antigens underlies the development of all autoimmune diseases, and despite progress, there remains a significant unmet need for patients.…
  • Abstract Number: 2256 • ACR Convergence 2024

    Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months

    Jia Yi Hee1, Hendrik Nel2, Yann Abraham3, Katrina Chakradeo4, Michelle Roch4, Tom Lynch5, Lyn March5, Mihir Wechalekar6, Helen Keen7 and Ranjeny Thomas8, 1The University of Queensland, Woolloongabba, Queensland, Australia, 2Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Janssen Research and Development, Beerse, Belgium, 4The University of Queensland, Brisbane, Australia, 5The University of Sydney, Sydney, New South Wales, Australia, 6Flinders Medical Centre, Adelaide, Australia, 7Fiona Stanley Hospital, Murdoch, Western Australia, Australia, 8University of Queensland, Brisbane, Australia

    Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
  • Abstract Number: 0078 • ACR Convergence 2023

    Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers

    Maria-Eugenia Miranda-Carus1, Beatriz Nieto-Carvalhal1, Irene Monjo2, Mariela Uyaguari-Morocho1, Alejandro Villalba3, Laura Nuño1, Diana Peiteado1, Elisa Fernández1, Sara García-Carazo1 and Alejandro Balsa4, 1Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 2University Hospital La Paz, Madrid, Spain, 3Rheumatology Department, La Paz University Hospital, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: CD4+CXCR5+PD-1hi follicular helper (Tfh) T cells dwell in the germinal centers (GCs), help B cells, and are implicated in Rheumatoid Arthritis (RA) pathogenesis. Circulating…
  • Abstract Number: 0210 • ACR Convergence 2023

    Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors

    Hilde Ørbo1, Asia-Sophia Wolf2, Kristin Hammersbøen Bjørlykke3, Sarah E. Josefsson2, Guri Solum2, Ingrid Fadum Kjønstad4, Ingrid Jyssum1, Ingrid Christensen1, Anne Therese Tveter1, Joseph Sexton1, Grete B. Kro5, Gunnveig Grødeland6, Tore Kvien1, Jørgen Jahnsen3, John Torgils Vaage7, Espen Haavardsholm1, Sella Provan8, Hassen Kared9, Ludvig A. Munthe7, Kristin Kaasen Jørgensen3, Silje Watterdal Syversen1, Siri Mjaaland2 and Guro Goll1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Norwegian Institute of Public Health, Oslo, Norway, 3Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 4National Institute of Public Health, Oslo, Norway, 5Department of Microbiology, Oslo University Hospital, Oslo, Norway, 6Department of Immunology, Oslo University Hospital, Oslo, Norway, 7Department of Immunology, Oslo University Hospital, Oslo, Norway, 8Diakonhjemmet Hospital, Oslo, Norway, 9Department of Immunology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: T cells are critical for control of viral infection with SARS-CoV-2, but knowledge is lacking on cellular immune responses following repeated vaccination and breakthrough…
  • Abstract Number: 0929 • ACR Convergence 2023

    Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms

    Reiko Takahashi and Yoshitaka Imura, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka, Japan

    Background/Purpose: SOCS1 (suppressor of cytokine signaling 1) is a suppressor molecule of the JAK/STAT pathway and has been reported to be involved in the pathogenesis…
  • Abstract Number: 1741 • ACR Convergence 2023

    The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis

    Sara Turcinov1, Charlotte de Vries2, Ravi Kumar Sharma2, Christina Gerstner2, Bruno Raposo2, Anatoly Dubnovitsky2, William Kwok3, Karine Chemin2, Vivianne Malmström4 and Aase Hensvold5, 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden, 5Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden

    Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
  • Abstract Number: 0079 • ACR Convergence 2023

    CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles

    Amit Lakhanpal1, Kazuyoshi Ishigaki2, Anvita Singaraju1, Alejandro Kochen3, Miriam Fein1, Soumya Raychaudhuri4 and Laura Donlin1, 1Hospital for Special Surgery, New York, NY, 2RIKEN, Tokyo, Japan, 3Yale School of Medicine, New Haven, CT, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A role for CD4 T cells in RA pathology is supported by the effectiveness of T cell therapies, genetic studies implicating T cell gene…
  • Abstract Number: 0279 • ACR Convergence 2023

    Therapeutic Exploration of Immune Checkpoint Inhibitor Induced Inflammatory Arthritis In Vivo

    Sang Kim1, Rene Rico2, Naimah Turner2, Trupti Trivedi2, Theresa Guise2 and Roza Nurieva2, 1The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, 2The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Despite unprecedented clinical success, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (ICI-arthritis). Management of ICI-arthritis is challenging because…
  • Abstract Number: 0931 • ACR Convergence 2023

    Down-Regulation of Human NADH-Ubiquinone Oxidoreductase Chain 6 by N6-Methyladenosine Methylation Is Associated with Lupus CD4+ T Cell Activation

    Miheraiy Abdukiyum1, Nan Zhao2, Yuanyuan Zheng1, Tohtihan Alim3, Xiaojun Tang1 and Xuebing Feng2, 1Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nan Jing, China, 2Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China, 3Nanjing University, Nanjing, China

    Background/Purpose: Recently mitochondria have been recognized as a key player in the pathogenesis of systemic lupus erythematosus (SLE). Given that N6-methyladenosine (m6A) modifications can regulate…
  • Abstract Number: 1762 • ACR Convergence 2023

    Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

    JING SONG1, Cliff Rims1, Matthew Dufort1, Peter Linsley1, Eddie James2 and Jane Buckner2, 1Benaroya Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 0080 • ACR Convergence 2023

    Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses

    Neha Bhagwat1, Kumar Penmetsa2, Matt Devalaraja3, Suzana Marusic4, Cornelia M. Weyand5, Shozo Ohtsuki6, Peggy Scherle1 and Kris Vaddi1, 1Prelude Therapeutics, Inc, Wilmington, DE, 2Thermo Fisher Scientific, Philadelphia, PA, 3Nipuna Therapeutics, Waltham, MA, 4Hooke Laboratories LLC, Lawrence, MA, 5Mayo Clinic School of Medicine and Stanford University, Rochester, MN, 6Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN

    Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology